Managlinat dialanetil, a fructose-1,6-bisphosphatase inhibitor for the treatment of type 2 diabetes

Curr Opin Investig Drugs. 2007 Oct;8(10):849-58.

Abstract

Metabasis Therapeutics Inc (formerly Gensia Sicor Inc, which became SICOR Inc), in collaboration with Daiichi Sankyo Co Ltd (formerly Sankyo Co Ltd) is developing the fructose-1,6-bisphosphatase inhibitor managlinat dialanetil, a low-molecular weight purine nucleotide analog that inhibits gluconeogenesis, for the potential treatment of type 2 diabetes. Phase II clinical trials of the compound are underway in Europe and the US.

Publication types

  • Review

MeSH terms

  • Alanine / adverse effects
  • Alanine / analogs & derivatives*
  • Alanine / metabolism
  • Alanine / pharmacokinetics
  • Alanine / therapeutic use
  • Animals
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Drug Evaluation, Preclinical
  • Fructose-Bisphosphatase / antagonists & inhibitors*
  • Humans
  • Hypoglycemic Agents* / adverse effects
  • Hypoglycemic Agents* / metabolism
  • Hypoglycemic Agents* / pharmacokinetics
  • Hypoglycemic Agents* / therapeutic use
  • Organophosphonates
  • Organophosphorus Compounds* / adverse effects
  • Organophosphorus Compounds* / metabolism
  • Organophosphorus Compounds* / pharmacokinetics
  • Organophosphorus Compounds* / therapeutic use
  • Structure-Activity Relationship

Substances

  • Hypoglycemic Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • N,N'-((5-(2-amino-5-(2-methylpropyl)-4-thiazolyl)-2-furanyl)phosphinylidene)bis(alanine) diethyl ester
  • Fructose-Bisphosphatase
  • Alanine